Skip to search formSkip to main contentSkip to account menu

EPO906

Known as: EPO-906A 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

epothilone B

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
A phase I study of celecoxib (C) and patupilone (EPO906) in patients (pts) with metastatic colorectal cancer (mCRC).
2533 Background: Patupilone (EPO906) is an epothilone that stabilizes microtubules leading to cell cycle arrest and apoptosis… 
2010
2010
Randomized phase II trial of patupilone plus prednisone versus docetaxel plus prednisone in patients with chemotherapy-naïve, metastatic, castrate-resistant prostate cancer (CRPC).
4553 Background: Docetaxel (Doc) + prednisone is considered the standard of care in first-line treatment of patients (pts) with… 
2010
2010
Preventing patupilone-induced diarrhea with high-dose corticosteroids.
e13069 Background: Patupilone (EPO906, Epothilone B) is a cytotoxic agent that induces mitotic cell cycle arrest and apoptosis in… 
2009
2009
Role of theMicroenvironment for Radiosensitization by Patupilone
Purpose:The combined treatment modality of ionizing radiation (IR) and the clinically relevant microtubule-stabilizing compound… 
2005
2005
InducedVascular Disruption in Orthotopic Rodent TumorModels Detected byMagnetic Resonance Imaging and Interstitial Fluid Pressure
Purpose: Evaluation of vascular disruptive activity in orthotopic models as potential surrogate biomarkers of tumor response to… 
2002
2002
EPO906 (Epothilone B) inhibits cell growth and survival of multiple myeloma cells in the bone marrow microenvironment, in vitro and in vivo.